Clinical considerations after endovascular therapy of peripheral artery disease

References

• Gerhard-Herman MD, Gornik HL, Barrett C, et al. **2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: executive summary: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. J Am Coll Cardiol. 2017;69(11):1465–1508.
   PubMed Web of Science ®Google Scholar
• Pande RL, Perlstein TS, Beckman JA, et al. Secondary prevention and mortality in peripheral artery disease: national health and nutrition examination study, 1999 to 2004. Circulation. 2011;124(1):17–23.
   PubMed Web of Science ®Google Scholar
• Fowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013;382(9901):1329–1340.
   PubMed Web of Science ®Google Scholar
• Sampson UK, Fowkes FG, McDermott MM, et al. Global and regional burden of death and disability from peripheral artery disease: 21 world regions, 1990 to 2010. Glob Heart. 2014;9(1):145–158.e121.
   PubMedGoogle Scholar
• Kim H, Kim S, Han S, et al. Prevalence and incidence of atherosclerotic cardiovascular disease and its risk factors in Korea: a nationwide population-based study. BMC Public Health. 2019;19(1):1112.
   PubMed Web of Science ®Google Scholar
• Golomb BA, Dang TT, Criqui MH. Peripheral arterial disease: morbidity and mortality implications. Circulation. 2006;114(7):688–699.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care. 2003;26(12):3333–3341.
   Google Scholar
• Mahmood SS, Levy D, Vasan RS, et al. The Framingham Heart Study and the epidemiology of cardiovascular disease: a historical perspective. Lancet. 2014;383(9921):999–1008.
   PubMed Web of Science ®Google Scholar
• McDermott MM, Liu K, Greenland P, et al. Functional decline in peripheral arterial disease: associations with the ankle brachial index and leg symptoms. Jama. 2004;292(4):453–461.
   PubMed Web of Science ®Google Scholar
• Fowkes FG, Price JF, Stewart MC, et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. Jama. 2010;303(9):841–848.
   PubMed Web of Science ®Google Scholar
• Criqui MH, Ninomiya JK, Wingard DL, et al. Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality. J Am Coll Cardiol. 2008;52(21):1736–1742.
   PubMed Web of Science ®Google Scholar
• Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381–386.
   PubMed Web of Science ®Google Scholar
• Norgren L, Hiatt WR, Dormandy JA, et al. Inter-society consensus for the management of peripheral arterial disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(Suppl 1):S1–75.
   PubMed Web of Science ®Google Scholar
• Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The task force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018;39(9):763–816.
   PubMed Web of Science ®Google Scholar
• Reiner Ž, De Sutter J, Ryden L, et al. Peripheral arterial disease and intermittent claudication in coronary heart disease patients. Int J Cardiol. 2021;322:227–232.
   PubMed Web of Science ®Google Scholar
• De Vriese AS, Verbeuren TJ, Van de Voorde J, et al. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000;130(5):963–974.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J. 1993;69(5):377–381.
   PubMedGoogle Scholar
• Tschoepe D, Roesen P, Kaufmann L, et al. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest. 1990;20(2):166–170.
   PubMed Web of Science ®Google Scholar
• Carr ME. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001;15(1):44–54.
   PubMed Web of Science ®Google Scholar
• Thiruvoipati T, Kielhorn CE, Armstrong EJ. Peripheral artery disease in patients with diabetes: epidemiology, mechanisms, and outcomes. World J Diabetes. 2015;6(7):961–969.
   PubMed Web of Science ®Google Scholar
• Paneni F, Costantino S, Cosentino F. Insulin resistance, diabetes, and cardiovascular risk. Curr Atheroscler Rep. 2014;16(7):419.
   PubMed Web of Science ®Google Scholar
• Conte MS, Bradbury AW, Kolh P, et al. Global vascular guidelines on the management of chronic limb-threatening ischemia. J Vasc Surg. 2019;69(6s):3S–125S.e140.
   PubMedGoogle Scholar
• Marston WA, Davies SW, Armstrong B, et al. Natural history of limbs with arterial insufficiency and chronic ulceration treated without revascularization. J Vasc Surg. 2006;44(1):108–114.
   PubMed Web of Science ®Google Scholar
• Saraidaridis JT, Ergul E, Patel VI, et al. The Society for Vascular Surgery’s objective performance goals for lower extremity revascularization are not generalizable to many open surgical bypass patients encountered in contemporary surgical practice. J Vasc Surg. 2015;62(2):392–400.
   PubMed Web of Science ®Google Scholar
• Goodney PP, Beck AW, Nagle J, et al. National trends in lower extremity bypass surgery, endovascular interventions, and major amputations. J Vasc Surg. 2009;50(1):54–60.
   PubMed Web of Science ®Google Scholar
• Agarwal S, Sud K, Shishehbor MH. Nationwide Trends of Hospital Admission and Outcomes Among Critical Limb Ischemia Patients: from 2003–2011. J Am Coll Cardiol. 2016;67(16):1901–1913.
   PubMed Web of Science ®Google Scholar
• Schillinger M, Minar E. Percutaneous treatment of peripheral artery disease: novel techniques. Circulation. 2012;126(20):2433–2440.
   PubMed Web of Science ®Google Scholar
• Armstrong EJ, Chen DC, Westin GG, et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc. 2014;3(2):e000697.
   PubMed Web of Science ®Google Scholar
• Wieczorek-Surdacka E, Świerszcz J, Surdacki A. Effects of atorvastatin dose and concomitant use of angiotensin-converting enzyme inhibitors on renal function changes over time in patients with stable coronary artery disease: a prospective observational study. Int J Mol Sci. 2016;17(2):106.
   PubMed Web of Science ®Google Scholar
• Armstrong EJ, Wu J, Singh GD, et al. Smoking cessation is associated with decreased mortality and improved amputation-free survival among patients with symptomatic peripheral artery disease. J Vasc Surg. 2014;60(6):1565–1571.
   PubMed Web of Science ®Google Scholar
• Chang SH, Tsai YJ, Chou HH, et al. Clinical predictors of long-term outcomes in patients with critical limb ischemia who have undergone endovascular therapy. Angiology. 2014;65(4):315–322.
   PubMed Web of Science ®Google Scholar
• O’Brien-Irr MS, Dosluoglu HH, Harris LM, et al. Outcomes after endovascular intervention for chronic critical limb ischemia. J Vasc Surg. 2011;53(6):1575–1581.
   PubMed Web of Science ®Google Scholar
• Krishnamurthy V, Munir K, Rectenwald JE, et al. Contemporary outcomes with percutaneous vascular interventions for peripheral critical limb ischemia in those with and without poly-vascular disease. Vasc Med. 2014;19(6):491–499.
   PubMed Web of Science ®Google Scholar
• Meltzer AJ, Shrikhande G, Gallagher KA, et al. Heart failure is associated with reduced patency after endovascular intervention for symptomatic peripheral arterial disease. J Vasc Surg. 2012;55(2):353–362.
   PubMed Web of Science ®Google Scholar
• Chen DC, Armstrong EJ, Singh GD, et al. Adherence to guideline-recommended therapies among patients with diverse manifestations of vascular disease. Vasc Health Risk Manag. 2015;11:185–192.
   PubMed Web of Science ®Google Scholar
• Feringa HH, Van Waning VH, Bax JJ, et al. Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. J Am Coll Cardiol. 2006;47(6):1182–1187.
   PubMed Web of Science ®Google Scholar
• Collaboration AT. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Bmj. 2002;324(7329):71–86.
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22.
   Google Scholar
• Kokkinidis DG, Arfaras-Melainis A, Giannopoulos S, et al. Statin therapy for reduction of cardiovascular and limb-related events in critical limb ischemia: a systematic review and meta-analysis. Vasc Med. 2020;25(2):106–117.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–153.
   PubMed Web of Science ®Google Scholar
• Aboyans V, Criqui MH, Abraham P, et al. Measurement and interpretation of the ankle-brachial index: a scientific statement from the American Heart Association. Circulation. 2012;126(24):2890–2909.
   PubMed Web of Science ®Google Scholar
• Zeller T, Dake MD, Tepe G, et al. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents. JACC Cardiovasc Interv. 2013;6(3):274–281.
   PubMed Web of Science ®Google Scholar
• Setacci C, Chisci E, De Donato G, et al. Subintimal angioplasty with the aid of a re-entry device for TASC C and D lesions of the SFA. Eur J Vasc Endovasc Surg. 2009;38(1):76–87.
   PubMed Web of Science ®Google Scholar
• Markose G, Miller FN, Bolia A. Subintimal angioplasty for femoro-popliteal occlusive disease. J Vasc Surg. 2010;52(5):1410–1416.
   PubMed Web of Science ®Google Scholar
• Selmon MR, Schwindt AG, Cawich IM, et al. Final results of the Chronic Total Occlusion Crossing With the Ocelot System II (CONNECT II) study. J Endovas Ther. 2013;20(6):770–781.
   PubMed Web of Science ®Google Scholar
• Aboyans V, Ricco J-B, Bartelink M-LE-L, et al. 2017 ESC guidelines on the diagnosis and treatment of peripheral arterial diseases, in collaboration with the European Society for Vascular Surgery (ESVS): document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesendorsed by: the European Stroke Organization (ESO)The task force for the diagnosis and treatment of peripheral arterial diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2017;39(9):763–816.
   Google Scholar
• Iida O, Soga Y, Hirano K, et al. Long-term results of direct and indirect endovascular revascularization based on the angiosome concept in patients with critical limb ischemia presenting with isolated below-the-knee lesions. J Vasc Surg. 2012;55(2):363–370.e365.
   PubMed Web of Science ®Google Scholar
• Mustapha JA, Anose BM, Martinsen BJ, et al. Lower extremity revascularization via endovascular and surgical approaches: a systematic review with emphasis on combined inflow and outflow revascularization. SAGE Open Med. 2020;8:2050312120929239.
   Web of Science ®Google Scholar
• Darling JD, McCallum JC, Soden PA, et al. Clinical results of single-vessel versus multiple-vessel infrapopliteal intervention. J Vasc Surg. 2016;64(6):1675–1681.
   PubMed Web of Science ®Google Scholar
• Schillinger M, Exner M, Mlekusch W, et al. Vascular inflammation and percutaneous transluminal angioplasty of the femoropopliteal artery: association with restenosis. Radiology. 2002;225(1):21–26.
   PubMed Web of Science ®Google Scholar
• Reijnen M, Van Wijck I, Zeller T, et al. Outcomes after drug-coated balloon treatment of femoropopliteal lesions in patients with critical limb ischemia: a post hoc analysis from the IN.PACT global study. J Endovas Ther. 2019;26(3):305–315.
   PubMed Web of Science ®Google Scholar
• Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131(5):495–502.
   PubMed Web of Science ®Google Scholar
• Rosenfield K, Jaff MR, White CJ, et al. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med. 2015;373(2):145–153.
   PubMed Web of Science ®Google Scholar
• Tepe G, Zeller T, Albrecht T, et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med. 2008;358(7):689–699.
   PubMed Web of Science ®Google Scholar
• Cassese S, Byrne RA, Ott I, et al. Paclitaxel-coated versus uncoated balloon angioplasty reduces target lesion revascularization in patients with femoropopliteal arterial disease: a meta-analysis of randomized trials. Circ Cardiovasc Interv. 2012;5(4):582–589.
   PubMed Web of Science ®Google Scholar
• Katsanos K, Spiliopoulos S, Kitrou P, et al. Risk of death following application of paclitaxel-coated balloons and stents in the femoropopliteal artery of the leg: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc. 2018;7(24):e011245.
   PubMed Web of Science ®Google Scholar
• Dake MD, Ansel GM, Jaff MR et al. Correction to: durable clinical effectiveness with paclitaxel-eluting stents in the femoropopliteal artery 5-year results of the zilver PTX randomized trial. Circulation. 2019;139(8):e42–e42
   Web of Science ®Google Scholar
• Weintraub WS. The pathophysiology and burden of restenosis. Am J Cardiol. 2007;100(5a):3k–9k.
   PubMed Web of Science ®Google Scholar
• Geary RL, Clowes AW. Epidemiology and pathogenesis of restenosis. In: Duckers H.J., Nabel E.G., Serruys P.W., editor. Essentials of restenosis. Springer; 2007. p. 7–28.
   Google Scholar
• González MV, Jiménez B, Berciano MT, et al. Glucocorticoids antagonize AP-1 by inhibiting the Activation/phosphorylation of JNK without affecting its subcellular distribution. J Cell Biol. 2000;150(5):1199–1208.
   PubMed Web of Science ®Google Scholar
• Rooke TW, Hirsch AT, Misra S, et al. 2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2011;124(18):2020–2045.
   PubMed Web of Science ®Google Scholar
• Katsanos K, Spiliopoulos S, Saha P, et al. Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: a systematic review and network meta-analysis. PLoS One. 2015;10(8):e0135692.
   PubMed Web of Science ®Google Scholar
• Hess CN, Norgren L, Ansel GM, et al. A structured review of antithrombotic therapy in peripheral artery disease with a focus on revascularization: a TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) initiative. Circulation. 2017;135(25):2534–2555.
   PubMed Web of Science ®Google Scholar
• Kim TI, Chen JF, Orion KC. Practice patterns of dual antiplatelet therapy after lower extremity endovascular interventions. Vasc Med. 2019;24(6):528–535.
   PubMed Web of Science ®Google Scholar
• Sobieszczyk P, Eisenhauer A. Management of patients after endovascular interventions for peripheral artery disease. Circulation. 2013;128(7):749–757.
   PubMed Web of Science ®Google Scholar
• Anand SS, Bosch J, Eikelboom JW, et al. Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219–229.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205–218.
   PubMed Web of Science ®Google Scholar
• Anand SS, Caron F, Eikelboom JW, et al. Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial. J Am Coll Cardiol. 2018;71(20):2306–2315.
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in peripheral artery disease after revascularization. N Engl J Med. 2020;382(21):1994–2004.
   PubMed Web of Science ®Google Scholar
• Calabrò P, Yeh ET. The pleiotropic effects of statins. Curr Opin Cardiol. 2005;20(6):541–546.
   PubMed Web of Science ®Google Scholar
• Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol. 2001;21(11):1712–1719.
   PubMed Web of Science ®Google Scholar
• Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89–118.
   PubMed Web of Science ®Google Scholar
• Antoniou GA, Hajibandeh S, Hajibandeh S, et al. Meta-analysis of the effects of statins on perioperative outcomes in vascular and endovascular surgery. J Vasc Surg. 2015;61(2):519–532.e511.
   PubMed Web of Science ®Google Scholar
• Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation. 2004;109(23Suppl 1):Iii39–43.
   PubMedGoogle Scholar
• Hooi JD, Kester AD, Stoffers HE, et al. Asymptomatic peripheral arterial occlusive disease predicted cardiovascular morbidity and mortality in a 7-year follow-up study. J Clin Epidemiol. 2004;57(3):294–300.
   PubMed Web of Science ®Google Scholar
• Linnemann B, Sutter T, Herrmann E, et al. Elevated cardiac troponin T is associated with higher mortality and amputation rates in patients with peripheral arterial disease. J Am Coll Cardiol. 2014;63(15):1529–1538.
   PubMed Web of Science ®Google Scholar
• Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25Pt B):2889–2934.
   PubMed Web of Science ®Google Scholar
• Fernandez N, McEnaney R, Marone LK, et al. Multilevel versus isolated endovascular tibial interventions for critical limb ischemia. J Vasc Surg. 2011;54(3):722–729.
   PubMed Web of Science ®Google Scholar
• Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J. 2004;25(1):17–24.
   PubMed Web of Science ®Google Scholar
• Bodewes TCF, Darling JD, O’Donnell TFX, et al. Long-term mortality benefit of renin-angiotensin system inhibitors in patients with chronic limb-threatening ischemia undergoing vascular intervention. J Vasc Surg. 2018;67(3):800–808.e801.
   PubMed Web of Science ®Google Scholar
• Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation. 2017;135(12):e726–e779.
   PubMed Web of Science ®Google Scholar
• Armstrong EJ, Chen DC, Singh GD, et al. Angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use is associated with reduced major adverse cardiovascular events among patients with critical limb ischemia. Vasc Med. 2015;20(3):237–244.
   PubMed Web of Science ®Google Scholar
• Hoeks SE, Scholte Op Reimer WJM, Van Gestel YRBM.et al. Medication underuse during long-term follow-up in patients with peripheral arterial disease. Circ Cardiovasc Qual Outcomes. 2009;2(4):338–343.
   PubMed Web of Science ®Google Scholar
• Ardati AK, Kaufman SR, Aronow HD, et al. The quality and impact of risk factor control in patients with stable claudication presenting for peripheral vascular interventions. Circ Cardiovasc Interv. 2012;5(6):850–855.
   PubMed Web of Science ®Google Scholar
• Baggish AL, Weiner RB, Kanayama G, et al. Cardiovascular toxicity of illicit anabolic-androgenic steroid use. Circulation. 2017;135(21):1991–2002.
   PubMed Web of Science ®Google Scholar
• Sandfort V, Bluemke DA, Vargas J, et al. Coronary plaque progression and regression in asymptomatic African American chronic cocaine users with obstructive coronary stenoses: a preliminary study. J Addict Med. 2017;11(2):126–137.
   PubMed Web of Science ®Google Scholar
• Dagenais GR, Yi Q, Lonn E, et al. Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial. Eur J Cardiovasc Prev Rehabil. 2005;12(1):75–81.
   PubMedGoogle Scholar
• Olin JW, Allie DE, Belkin M, et al. ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures, the American College of Radiology, the Society for Cardiac Angiography and Interventions, the Society for Interventional Radiology, the Society for Vascular Medicine, the Society for Vascular Nursing, and the Society for Vascular Surgery (Writing Committee to Develop Clinical Performance Measures for Peripheral Artery Disease). Developed in collaboration with the American Association of Cardiovascular and Pulmonary Rehabilitation; the American Diabetes Association; the Society for Atherosclerosis Imaging and Prevention; the Society for Cardiovascular Magnetic Resonance; the Society of Cardiovascular Computed Tomography; and the PAD Coalition. Endorsed by the American Academy of Podiatric Practice Management. J Vasc Surg. 2010;52(6):1616–1652.
   PubMedGoogle Scholar
• Smith SC Jr., Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation. 2011;124(22):2458–2473.
   PubMed Web of Science ®Google Scholar
• Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. Jama. 2001;286(11):1317–1324.
   PubMed Web of Science ®Google Scholar
• Subherwal S, Patel MR, Kober L, et al. Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. Circulation. 2012;126(11):1345–1354.
   PubMed Web of Science ®Google Scholar
• McDermott MM, Hahn EA, Greenland P, et al. Atherosclerotic risk factor reduction in peripheral arterial diseasea: results of a national physician survey. J Gen Intern Med. 2002;17(12):895–904.
   PubMed Web of Science ®Google Scholar
• Al-Omran M. Knowledge and attitude of physicians in a major teaching hospital towards atherosclerotic risk reduction therapy in patients with peripheral arterial disease. Vasc Health Risk Manag. 2007;3(6):1019–1027.
   PubMedGoogle Scholar
• Hirsch AT, Murphy TP, Lovell MB, et al. Gaps in public knowledge of peripheral arterial disease: the first national PAD public awareness survey. Circulation. 2007;116(18):2086–2094.
   PubMed Web of Science ®Google Scholar
• Rooke TW, Hirsch AT, Misra S, et al. Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61(14):1555–1570.
   PubMedGoogle Scholar
• Tendera M, Aboyans V, Bartelink ML, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851–2906.
   PubMed Web of Science ®Google Scholar
• Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45 Suppl S:S5–67.
   PubMed Web of Science ®Google Scholar
• Michalska M, Kazimierczak W, Leszczyński W, et al. Contemporary follow-up imaging after endovascular repair of lower extremity atherosclerotic lesions. Pol J Radiol. 2018;83:e634–e642.
   PubMed Web of Science ®Google Scholar
• Kazimierczak W, Serafin Z, Kazimierczak N, et al. Contemporary imaging methods for the follow-up after endovascular abdominal aneurysm repair: a review. Wideochir Inne Tech Maloinwazyjne. 2019;14(1):1–11.
   PubMedGoogle Scholar
• Serafin Z, Karolkiewicz M, Gruszka M, et al. High incidence of nephropathy in neurosurgical patients after intra-arterial administration of low-osmolar and iso-osmolar contrast media. Acta Radiol. 2011;52(4):422–429.
   PubMed Web of Science ®Google Scholar
• Maintz D, Tombach B, Juergens KU, et al. Revealing in-stent stenoses of the iliac arteries: comparison of multidetector CT with MR angiography and digital radiographic angiography in a Phantom model. AJR Am J Roentgenol. 2002;179(5):1319–1322.
   PubMed Web of Science ®Google Scholar
• Małek G, Elwertowski M, Nowicki A. Standards of the polish ultrasound society– update. ultrasound examination of the aorta and arteries of the lower extremities. J Ultrason. 2014;14(57):192–202.
   PubMedGoogle Scholar
• Mills JL Sr., Conte MS, Armstrong DG, et al. The society for vascular surgery lower extremity threatened limb classification system: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg. 2014;59(1):220–234.e221–222.
   Web of Science ®Google Scholar
• Tam M, Ahnood D, Tanqueray A, et al. Endovascular treatment of a superficial femoral artery aneurysm using an Amplatzer Vascular Plug. Diagn Interv Radiol. 2013;19(6):516–517.
   PubMed Web of Science ®Google Scholar
• Barleben A, Bandyk DF. Surveillance and follow-up after revascularization for critical limb ischemia. Semin Vasc Surg. 2014;27(1):75–81.
   PubMed Web of Science ®Google Scholar
• Connors G, Todoran TM, Engelson BA, et al. Percutaneous revascularization of long femoral artery lesions for claudication: patency over 2.5 years and impact of systematic surveillance. Catheter Cardiovasc Interv. 2011;77(7):1055–1062.
   PubMed Web of Science ®Google Scholar
• Dick F, Ricco JB, Davies AH, et al. Chapter VI: follow-up after revascularisation. Eur J Vasc Endovasc Surg. 2011;42(Suppl 2):S75–90.
   PubMedGoogle Scholar
• Gorely T, Crank H, Humphreys L, et al. “Standing still in the street”: experiences, knowledge and beliefs of patients with intermittent claudication–a qualitative study. J Vasc Nurs. 2015;33(1):4–9.
   PubMed Web of Science ®Google Scholar
• Cunningham MA, Swanson V, Pappas E, et al. Illness beliefs and walking behavior after revascularization for intermittent claudication: a qualitative study. J Cardiopulm Rehabil Prev. 2014;34(3):195–201.
   PubMed Web of Science ®Google Scholar
• McDermott MM, Liu K, Ferrucci L, et al. Greater sedentary hours and slower walking speed outside the home predict faster declines in functioning and adverse calf muscle changes in peripheral arterial disease. J Am Coll Cardiol. 2011;57(23):2356–2364.
   PubMed Web of Science ®Google Scholar
• Hiatt WR, Regensteiner JG, Hargarten ME, et al. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation. 1990;81(2):602–609.
   PubMed Web of Science ®Google Scholar
• Hiatt WR, Wolfel EE, Meier RH, et al. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation. 1994;90(4):1866–1874.
   PubMed Web of Science ®Google Scholar
• Hiatt WR, Regensteiner JG, Wolfel EE, et al. Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease. J Appl Physiol (1985). 1996;81(2):780–788.
   PubMed Web of Science ®Google Scholar
• Chang P, Nead KT, Olin JW, et al. Effect of physical activity assessment on prognostication for peripheral artery disease and mortality. Mayo Clin Proc. 2015;90(3):339–345.
   PubMed Web of Science ®Google Scholar
• Sakamoto S, Yokoyama N, Tamori Y, et al. Patients with peripheral artery disease who complete 12-week supervised exercise training program show reduced cardiovascular mortality and morbidity. Circ J. 2009;73(1):167–173.
   PubMed Web of Science ®Google Scholar
• Mays RJ, Rogers RK, Hiatt WR, et al. Community walking programs for treatment of peripheral artery disease. J Vasc Surg. 2013;58(6):1678–1687.
   PubMed Web of Science ®Google Scholar
• Leng GC, Fowkes FG, Lee AJ, et al. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. Bmj. 1996;313(7070):1440–1444.
   PubMedGoogle Scholar
• Hiatt WR, Goldstone J, Smith SC Jr., et al. Atherosclerotic peripheral vascular disease symposium II: nomenclature for vascular diseases. Circulation. 2008;118(25):2826–2829.
   PubMed Web of Science ®Google Scholar
• Poredos P, Jug B. The prevalence of peripheral arterial disease in high risk subjects and coronary or cerebrovascular patients. Angiology. 2007;58(3):309–315.
   PubMed Web of Science ®Google Scholar
• Rhee SY, Kim YS. Peripheral arterial disease in patients with type 2 diabetes mellitus. Diabetes Metab J. 2015;39(4):283–290.
   PubMed Web of Science ®Google Scholar
• Varu VN, Hogg ME, Kibbe MR. Critical limb ischemia. J Vasc Surg. 2010;51(1):230–241.
   PubMed Web of Science ®Google Scholar